

Hepatitis A, B, and Combination A/B Vaccines

Vaccine Description See package inserts for specific vaccine components	Hepatitis A: Vaqta and Havrix	
	<ul style="list-style-type: none"> • Inactivated whole virus • Adjuvant: aluminum hydroxide • Vial stopper and/or the syringe plunger stopper may contain dry natural latex rubber 	
	Hepatitis B: Heplisav-B, Recombivax HB, Engerix-B	
	<ul style="list-style-type: none"> • Subunit viral antigen vaccine • Vial stoppers are not made with natural latex rubber • Heplisav-B adjuvant: CpG, DNA, innate immunity activator 	
	Combination Hepatitis A and B: Twinrix	
	<ul style="list-style-type: none"> • Bivalent vaccine containing the antigenic components used in producing Havrix and Engerix-B • Tip caps of the prefilled syringes contain natural rubber latex; the plungers are not made with natural rubber latex 	
Route (all)	<ul style="list-style-type: none"> • IM (Precaution: hemophilia, thrombocytopenia, and anticoagulation therapy) 	
Vaccine	Age	Dose
Hepatitis A (Vaqta)	6 months-18 years	25 units (0.5 mL)
	19 years and older	50 units (1 mL)
Hepatitis A (Havrix)	6 months-18 years	720 EL.U. (0.5 mL)
	19 years and older	1440 EL.U. (1 mL)
Hepatitis B (Engerix-B)	0-19 years	0.5 mL
	20 years and older	1 mL
Hepatitis B (Recombivax HB)	0-19 years	0.5 mL
	20 years and older	1 mL
Hepatitis B (Heplisav-B)	18 years and older	0.5 mL
Hepatitis A/Hepatitis B (Twinrix)	18 years and older	1 mL

Continued on Next Page

Hepatitis A, B, and Combination A/B Vaccines (Continued)

Indications	Hepatitis A
	<ul style="list-style-type: none"> • All persons aged > 1 year infected with human immunodeficiency virus (HIV) • All persons with chronic liver disease • Pregnant women at risk for hepatitis A infection (HAV) during pregnancy • All persons aged > 1 year, at risk for infection or severe disease from HAV during hepatitis A outbreaks • Persons providing services to adults in which a high proportion of those persons have risk factors for HAV infection • Persons aged > 1 year at risk for HAV infection or for severe disease from HAV including: <ul style="list-style-type: none"> ○ International travelers ○ men who have sex with men ○ persons who use injection or non-injection illegal drugs ○ persons with occupational risk for exposure ○ persons who anticipate close personal contact with an international adoptee ○ persons experiencing homelessness ○ persons requesting protection • All military personnel
	Hepatitis B
	<ul style="list-style-type: none"> • All children and adolescents • All military personnel • Household members and sexual partners of HBV carriers (test and if susceptible, vaccinate) • Intravenous drug users • Any person with more than one sex partner in 6 months • Men who have sex with men • People with recently diagnosed sexually transmitted diseases (STDs) • Persons with HIV • Persons with diabetes • Persons with chronic liver disease • Patients receiving hemodialysis and patients with renal disease that may result in dialysis • Recipients of certain bloodproducts • Healthcare and public safety workers with frequent blood contact • Residents and staff of institutions for people with developmental disabilities • Long-term prison inmates • Certain international travelers (Determine risk by checking CDC or ther travel medicine websites or check with local travel clinic for guidance) • People who want to decrease their risk for hepatitis B

Hepatitis A, B, and Combination A/B Vaccines (Continued)

Administration Schedule	Dose	Interval
Hepatitis A (Vaqta - 2 doses)	#1	N/A
	#1 to #2	6 months
Hepatitis A (Havrix - 2 doses)	#1	N/A
	#1 to #2	6 months
Hepatitis B (Engerix-B) - 3 doses)	#1	N/A
	#1 to #2	4 weeks
	#2 to #3	8 weeks minimum, 16 weeks after dose #1
Hepatitis B (Recombivax HB - 3 doses)	#1	N/A
	#1 to #2	4 weeks
	#2 to #3	8 weeks minimum, 16 weeks after dose #1
* Hepatitis B (HepSav-B - 2 doses)	#1	N/A
	#1 to #2	4 weeks minimum
** Hepatitis A + Hepatitis B (Twinrix)	#1	N/A
	#1 to #2	4 weeks
	#2 to #3	5 months
Twinrix (accelerated)	3 doses: 0, 7 days, and 21-30 days. Booster at 12 months.	
<p>* Note: The 2-dose HepB vaccine series only applies when both doses in the series consist of HepB-CpG. Series consisting of a combination of 1 dose of HepB-CpG and a vaccine from a different manufacturer should consist of 3 total vaccine doses and should adhere to the 3-dose schedule minimum intervals of 4 weeks between dose 1 and 2, 8 weeks between dose 2 and 3, and 16 weeks between dose 1 and 3. Doses administered at less than the minimum interval should be repeated. However, a series containing 2 doses of HepB-CpG administered at least 4 weeks apart is valid, even if the patient received a single earlier dose from another manufacturer.</p>		
<p>** If combining regimen of Twinrix® with individual doses of HepA and HepB vaccines, see info paper for number of doses needed (www.health.mil/HepA)</p>		

Hepatitis A, B, and Combination A/B Vaccines (Continued)

Contraindications	<ul style="list-style-type: none"> • Serious allergic reaction to prior dose or vaccine component, including yeast and neomycin • Moderate or severe acute illness • Pregnancy and breastfeeding are NOT contraindications
Special Considerations	Hepatitis A
	<ul style="list-style-type: none"> • Start vaccine series at least 2-4 weeks before international traveling • If first dose is given less than 4 weeks before international travel, consider giving IG as well as vaccine • Close contact of international adoptee (e.g., household or regular babysitting), within 60 days of arrival from country with high or intermediate endemic hepatitis A (administer dose 1 as soon as adoption is planned, at least 2 weeks before adoptee's arrival) • If dose #2 is delayed, do not repeat dose #1; just give dose #2. • See Storage and Handling Section
	Hepatitis B
	<ul style="list-style-type: none"> • If the series is delayed between doses, DO NOT start the series over. Continue from where you left off. • For vaccine non-responders (negative Hep B Ab titers), consult allergy/immunology, DHA-IHD, infectious disease • See Storage and Handling Section
<p>VIS: http://www.cdc.gov/vaccines/hcp/vis/vis-statements/hep-a.html http://www.cdc.gov/vaccines/hcp/vis/vis-statements/hep-b.html</p> <p>Additional education may be found at www.health.mil/hepA www.health.mil/hepB</p> <p>Pregnancy registry for Twinrix®: 1-888-825-5249 (GlaxoSmithKline); also notify DHA-IHD</p>	